India is set to make it mandatory for drug manufacturers to conduct annual audits of their raw material suppliers, following concerns about the safety of its pharmaceutical industry. The move comes in the wake of reports linking India-made cough syrups to the deaths of 141 children worldwide. The World Health Organization (WHO) and other health agencies have connected contaminated Indian cough syrups to fatalities in several countries. The new mandate and additional testing regulations introduced in June reflect India's efforts to reassure the global community about the safety of its $42 billion pharmaceutical industry. Drugmakers must also report all product recalls to their licensing authorities. These steps aim to enhance trust in the quality of Indian pharmaceutical products and reduce the risk of product failure. India's pharmaceutical sector needs help meeting global healthcare standards, particularly for small companies with limited resources.